RT Journal Article
T1 Emerging Roles of Lysyl Oxidases in the Cardiovascular System: New Concepts and Therapeutic Challenges
A1 Martínez González, José
A1 Varona, Saray
A1 Cañes, Laia
A1 Galán, María
A1 Briones, Ana
A1 Cachofeiro Ramos, María Victoria
A1 Rodríguez, Cristina
AB Lysyl oxidases (LOX and LOX-likes (LOXLs) isoenzymes) belong to a family of copper-dependent enzymes classically involved in the covalent cross-linking of collagen and elastin, a pivotal process that ensures extracellular matrix (ECM) stability and provides the tensile and elastic characteristics of connective tissues. Besides this structural role, in the last years, novel biological properties have been attributed to these enzymes, which can critically influence cardiovascular function. LOX and LOXLs control cell proliferation, migration, adhesion, differentiation, oxidative stress, and transcriptional regulation and, thereby, their dysregulation has been linked to a myriad of cardiovascular pathologies. Lysyl oxidase could modulate virtually all stages of the atherosclerotic process, from endothelial dysfunction and plaque progression to calcification and rupture of advanced and complicated plaques, and contributes to vascular stiffness in hypertension. The alteration of LOX/LOXLs expression underlies the development of other vascular pathologies characterized by a destructive remodeling of the ECM, such as aneurysm and artery dissections, and contributes to the adverse myocardial remodeling and dysfunction in hypertension, myocardial infarction, and obesity. This review examines the most recent advances in the study of LOX and LOXLs biology and their pathophysiological role in cardiovascular diseases with special emphasis on their potential as therapeutic targets.
PB MDPI
SN 2218-273X
YR 2019
FD 2019-10-14
LK https://hdl.handle.net/20.500.14352/12560
UL https://hdl.handle.net/20.500.14352/12560
LA eng
NO Martínez González, J., Varona, S., Cañes, L. et al. «Emerging Roles of Lysyl Oxidases in the Cardiovascular System: New Concepts and Therapeutic Challenges». Biomolecules, vol. 9, n.o 10, octubre de 2019, p. 610. DOI.org (Crossref), https://doi.org/10.3390/biom9100610.
NO Ministerio de Economía, Comercio y Empresa (España)
NO Instituto de Salud Carlos III
NO Agencia de Gestio d’Ajuts Universitaris i de Recerca
DS Docta Complutense
RD 9 abr 2025